Towards Healthcare
Percutaneous Nephrolithotomy (PCNL) System Market to Rise at 7.25% CAGR till 2...

Percutaneous Nephrolithotomy (PCNL) System Market Fueled by Single-Use Tech

According to forecasts, the global percutaneous nephrolithotomy (PCNL) system market will grow from USD 1.34 billion in 2024 to USD 2.7 billion by 2034, with an expected CAGR of 7.25%. The increasing cases of kidney stones are impacting the global market expansion. Due to the rising government funding for research and the wider adoption of medical devices are assisting North America’s market is being assisted.

Content

  • Last Updated: 31 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The percutaneous nephrolithotomy (PCNL) system market stands at USD 1.44 billion in 2025 and is expected to reach USD 2.7 billion by 2034, growing at a CAGR of 7.25% from 2024 to 2034.

North America is currently leading the percutaneous nephrolithotomy (PCNL) system market share by 38% due to the favorable reimbursement policies and government funding.

The percutaneous nephrolithotomy (PCNL) system market includes five segments such as by product system component, by procedure type approach, by device type, by end-user facility type, and by region.

Some key players include Boston Scientific Corporation, Olympus Corporation, Karl Storz SE & Co. KG, Cook Medical LLC, and Richard Wolf GmbH.

 Large stones, mainly those over 2 cm, staghorn calculi, and stones resistant to other treatments, including shock wave lithotripsy (ESWL) or ureteroscopy. 

NIH, US FDA, MedlinePlus.gov, ClinicalTrials.gov, NIDDK, PMNDP, OPM, AUA. NHS.UK, AHRQ.
Any Questions